We employed drug-target Mendelian randomization (MR) to systematically evaluate the effect of 5 approved or emerging lipid-perturbing drug targets for CVD (APOC3, ANGPTL3, ANGPTL4, CETP, and PCSK9) on risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). Here, PCSK9 is linked to cancer.